Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Alder Biopharmaceuticals Company Profile (NASDAQ:ALDR)

Consensus Ratings for Alder Biopharmaceuticals (NASDAQ:ALDR) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $31.67 (26.16% upside)

Analysts' Ratings History for Alder Biopharmaceuticals (NASDAQ:ALDR)
Show:
DateFirmActionRatingPrice TargetDetailsShare
3/5/2015Leerink SwannBoost Price TargetOutperform$24.00 -> $31.00ViewTweet This Rating  Share This Rating on StockTwits
12/17/2014Credit Suisse Group AGBoost Price TargetOutperform$19.00 -> $34.00ViewTweet This Rating  Share This Rating on StockTwits
9/2/2014Leerink SwannLower Price Target$26.00 -> $24.00ViewTweet This Rating  Share This Rating on StockTwits
6/11/2014Sanford C. BernsteinInitiated CoverageOutperform$30.00ViewTweet This Rating  Share This Rating on StockTwits
6/2/2014Credit Suisse Group AGInitiated CoverageOutperform$20.00ViewTweet This Rating  Share This Rating on StockTwits
6/2/2014Wells Fargo & Co.Initiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
6/2/2014Leerink SwannInitiated CoverageOutperform$26.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 4/25/2013 forward)